122 related articles for article (PubMed ID: 25871618)
41. Problems with the diagnosis of metastatic neuroendocrine neoplasms. Which diagnostic criteria should we use to determine tumor origin and help guide therapy?
Koo J; Dhall D
Semin Diagn Pathol; 2015 Nov; 32(6):456-68. PubMed ID: 26573790
[TBL] [Abstract][Full Text] [Related]
42. Cyclooxygenase-2 expression in gastroenteropancreatic neuroendocrine tumors.
Ince AT; Ovünç O; Celikel CA; Göksel S; Tosun S; Peker O
Hepatogastroenterology; 2007 Jun; 54(76):1125-9. PubMed ID: 17629053
[TBL] [Abstract][Full Text] [Related]
43. Serine protease inhibitor 8 is a novel immunohistochemical marker for neuroendocrine tumors of the pancreas.
de Koning PJ; Bovenschen N; Broekhuizen R; Lips CJ; Kummer JA
Pancreas; 2009 May; 38(4):461-7. PubMed ID: 19188865
[TBL] [Abstract][Full Text] [Related]
44. Neuropilin-2 is a novel marker expressed in pancreatic islet cells and endocrine pancreatic tumours.
Cohen T; Herzog Y; Brodzky A; Greenson JK; Eldar S; Gluzman-Poltorak Z; Neufeld G; Resnick MB
J Pathol; 2002 Sep; 198(1):77-82. PubMed ID: 12210066
[TBL] [Abstract][Full Text] [Related]
45. Nuclear survivin is a powerful novel prognostic marker in gastroenteropancreatic neuroendocrine tumor disease.
Grabowski P; Griss S; Arnold CN; Hörsch D; Göke R; Arnold R; Heine B; Stein H; Zeitz M; Scherübl H
Neuroendocrinology; 2005; 81(1):1-9. PubMed ID: 15809513
[TBL] [Abstract][Full Text] [Related]
46. Well-differentiated neuroendocrine tumors in skin: Terminology and diagnostic utility of cytokeratin 5/6 and p63.
Panse G; Cowper SE; Leffell DJ; Pulitzer M; Ko CJ
J Cutan Pathol; 2017 Jun; 44(6):557-562. PubMed ID: 28417484
[TBL] [Abstract][Full Text] [Related]
47. Classification of low-grade neuroendocrine tumors of midgut and unknown origin.
Van Eeden S; Quaedvlieg PF; Taal BG; Offerhaus GJ; Lamers CB; Van Velthuysen ML
Hum Pathol; 2002 Nov; 33(11):1126-32. PubMed ID: 12454818
[TBL] [Abstract][Full Text] [Related]
48. Pancreatic endocrine tumors: diagnostic pitfalls.
Ectors N
Hepatogastroenterology; 1999; 46(26):679-90. PubMed ID: 10370596
[No Abstract] [Full Text] [Related]
49. Intra-operative procedures to localize endocrine tumours of the pancreas and duodenum.
Norton JA
Ital J Gastroenterol Hepatol; 1999 Oct; 31 Suppl 2():S195-7. PubMed ID: 10604129
[TBL] [Abstract][Full Text] [Related]
50. Thyroid transcription factor-1 is expressed in extrapulmonary small cell carcinomas but not in other extrapulmonary neuroendocrine tumors.
Agoff SN; Lamps LW; Philip AT; Amin MB; Schmidt RA; True LD; Folpe AL
Mod Pathol; 2000 Mar; 13(3):238-42. PubMed ID: 10757334
[TBL] [Abstract][Full Text] [Related]
51. [Diagnostic criteria and classification of gastro-intestinal pancreatic endocrine tumors].
Capella C; Uccella S; Albarello L; Feltri M; La Rosa S
Minerva Endocrinol; 2001 Sep; 26(3):103-10. PubMed ID: 11753231
[TBL] [Abstract][Full Text] [Related]
52. Expression of CD24, a Stem Cell Marker, in Pancreatic and Small Intestinal Neuroendocrine Tumors.
Salaria S; Means A; Revetta F; Idrees K; Liu E; Shi C
Am J Clin Pathol; 2015 Oct; 144(4):642-8. PubMed ID: 26386086
[TBL] [Abstract][Full Text] [Related]
53. [Chromogranin A and neuroendocrine tumors].
Díaz Pérez JÁ; Currás Freixes M
Endocrinol Nutr; 2013; 60(7):386-95. PubMed ID: 23271036
[TBL] [Abstract][Full Text] [Related]
54. SATB2 is a sensitive marker for lower gastrointestinal well-differentiated neuroendocrine tumors.
Li Z; Yuan J; Wei L; Zhou L; Mei K; Yue J; Gao H; Zhang M; Jia L; Kang Q; Huang X; Cao D
Int J Clin Exp Pathol; 2015; 8(6):7072-82. PubMed ID: 26261600
[TBL] [Abstract][Full Text] [Related]
55. Endoscopic ultrasound-guided fine-needle aspiration cytology of pancreatic neuroendocrine tumors: a study of 48 cases.
Chatzipantelis P; Salla C; Konstantinou P; Karoumpalis I; Sakellariou S; Doumani I
Cancer; 2008 Aug; 114(4):255-62. PubMed ID: 18618505
[TBL] [Abstract][Full Text] [Related]
56. The importance of clinical information in patients with gastroenteropancreatic neuroendocrine tumor.
Kudo A; Akashi T; Kumagai J; Ban D; Inokuchi M; Kojima K; Kawano T; Tanaka S; Arii S
Hepatogastroenterology; 2012; 59(120):2450-3. PubMed ID: 22584507
[TBL] [Abstract][Full Text] [Related]
57. Immunohistochemical expression and prognostic value of ER, PR and HER2/neu in pancreatic and small intestinal neuroendocrine tumors.
Arnason T; Sapp HL; Barnes PJ; Drewniak M; Abdolell M; Rayson D
Neuroendocrinology; 2011; 93(4):249-58. PubMed ID: 21487213
[TBL] [Abstract][Full Text] [Related]
58. The diagnosis and medical management of advanced neuroendocrine tumors.
Kaltsas GA; Besser GM; Grossman AB
Endocr Rev; 2004 Jun; 25(3):458-511. PubMed ID: 15180952
[TBL] [Abstract][Full Text] [Related]
59. Low accuracy of tumor markers for diagnosing pancreatic neuroendocrine tumors in multiple endocrine neoplasia type 1 patients.
de Laat JM; Pieterman CR; Weijmans M; Hermus AR; Dekkers OM; de Herder WW; van der Horst-Schrivers AN; Drent ML; Bisschop PH; Havekes B; Vriens MR; Valk GD
J Clin Endocrinol Metab; 2013 Oct; 98(10):4143-51. PubMed ID: 23956349
[TBL] [Abstract][Full Text] [Related]
60. Ki67 labeling index in neuroendocrine tumors of the gastrointestinal and pancreatobiliary tract: to count or not to count is not the question, but rather how to count.
Adsay V
Am J Surg Pathol; 2012 Dec; 36(12):1743-6. PubMed ID: 23154766
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
